AI Drug Developer Derui Smart Medicine Secures $52 Million Series B Funding
Derui Smart Medicine (德睿智药), an AI-native biopharmaceutical company, has successfully closed a $52 million Series B funding round, with participation from leading domestic and international funds. The company was advised by Kairong Capital as the exclusive financial advisor. The newly raised capital will be allocated to further develop its AI drug discovery engine, the Molecule Arts Platform (MAP). This includes enhancing its Multi-Agent collaboration system and Clinical Data-in-the-Loop capabilities. Additionally, the funds will support the Phase III clinical trials and commercialization of its proprietary oral GLP-1 small molecule drug, MDR-001, and advance its pipeline of other innovative drug candidates.
Derui Smart Medicine aims to revolutionize traditional drug discovery, which often involves extensive trial-and-error synthesis of numerous molecules. CEO Niu Zhangming, who has extensive experience as a CTO at a German AI healthcare company, believes AI can transform this process into a data-driven, standardized, and iterative creation method. The MAP platform is structured in three layers: the AI design layer integrates proprietary platforms for biological, small molecule, and structural biology, covering the entire preclinical to IND submission process for various drug types. The second layer comprises experimental platforms that generate high-quality data to train AI models, with the company operating its own GPU clusters for foundational model training. The third layer, the Clinical Pro AI platform, uniquely incorporates clinical feedback into the R&D system to refine computational and experimental predictions, a key differentiator for the company. This platform has already accumulated over 1,300 de-identified clinical data points from its GLP-1 pipeline, MDR-001.
MDR-001, the first drug developed using MAP, entered Phase III clinical trials in late 2025. The company has recruited 760 participants in China across nearly 50 clinical centers and anticipates potential market launch within the next 2-3 years, targeting the substantial GLP-1 market. Derui Smart Medicine reports that MDR-001's development from preclinical candidate confirmation to Phase III initiation took approximately 4.5 years and cost around $23 million, a pace they claim is over 10 times faster than industry averages. Despite a team of just over 40 individuals, Derui Smart Medicine has advanced 15 innovative pipelines, secured 5 preclinical candidates, and obtained 3 IND approvals in China and the US. The company aspires to become an AI-era equivalent of Vertex Pharmaceuticals, leveraging its MAP system to create a continuous R&D flywheel that drives the development and commercialization of globally competitive new drugs.
AI-driven drug discovery platforms like Derui Smart Medicine's MAP represent a significant shift in pharmaceutical R&D, moving towards a more predictable and efficient model. By integrating AI design, experimental validation, and crucial clinical feedback loops, the company aims to reduce the historically high costs and lengthy timelines associated with bringing new drugs to market. The success of this approach hinges on the platform's ability to generate reliable predictive models and efficiently translate them into viable clinical candidates. The company's focus on a 'Clinical Data-in-the-Loop' system suggests a strategy to continuously refine its AI capabilities, creating a sustainable competitive advantage. As AI becomes more integrated into scientific discovery, the valuation of companies like Derui Smart Medicine may transcend traditional biotech metrics, reflecting the value of their proprietary technology and accelerated R&D processes. The challenge will be to consistently demonstrate the superiority of this AI-native approach over established methods, particularly in navigating the complex regulatory pathways and demonstrating clear clinical efficacy and safety in large-scale trials.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.